The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic

Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Gianmarco Contino

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)


Esophageal adenocarcinoma (EAC) is a poor-prognosis cancer type with rapidly rising incidence. Understanding of the genetic events driving EAC development is limited, and there are few molecular biomarkers for prognostication or therapeutics. Using a cohort of 551 genomically characterized EACs with matched RNA sequencing data, we discovered 77 EAC driver genes and 21 noncoding driver elements. We identified a mean of 4.4 driver events per tumor, which were derived more commonly from mutations than copy number alterations, and compared the prevelence of these mutations to the exome-wide mutational excess calculated using non-synonymous to synonymous mutation ratios (dN/dS). We observed mutual exclusivity or co-occurrence of events within and between several dysregulated EAC pathways, a result suggestive of strong functional relationships. Indicators of poor prognosis (SMAD4 and GATA4) were verified in independent cohorts with significant predictive value. Over 50% of EACs contained sensitizing events for CDK4 and CDK6 inhibitors, which were highly correlated with clinically relevant sensitivity in a panel of EAC cell lines and organoids.

Original languageEnglish
Pages (from-to)506-516
Number of pages16
JournalNature Genetics
Issue number3
Early online date4 Feb 2019
Publication statusPublished - Mar 2019


  • Adenocarcinoma/genetics
  • Biomarkers, Tumor/genetics
  • Cohort Studies
  • DNA Copy Number Variations/genetics
  • Esophageal Neoplasms/genetics
  • Exome/genetics
  • Female
  • Gene Expression Profiling/methods
  • Gene Expression Regulation, Neoplastic/genetics
  • Genomics/methods
  • Humans
  • Male
  • Mutation/genetics


Dive into the research topics of 'The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic'. Together they form a unique fingerprint.

Cite this